Previous close | 12.01 |
Open | 11.97 |
Bid | 11.98 x 800 |
Ask | 12.06 x 1800 |
Day's range | 11.96 - 12.04 |
52-week range | 11.11 - 12.81 |
Volume | |
Avg. volume | 152,495 |
Market cap | 423.139M |
Beta (5Y monthly) | 0.62 |
PE ratio (TTM) | 6.94 |
EPS (TTM) | 1.73 |
Earnings date | N/A |
Forward dividend & yield | 1.40 (11.69%) |
Ex-dividend date | 14 Nov 2023 |
1y target est | N/A |
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research. This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.
NEW YORK, December 22, 2022--Today, BlackRock Enhanced Government Fund, Inc. (NYSE: EGF), BlackRock Debt Strategies Fund, Inc. (NYSE: DSU), BlackRock Floating Rate Income Strategies Fund, Inc. (NYSE: FRA), BlackRock Floating Rate Income Trust (NYSE: BGT), BlackRock Corporate High Yield Fund, Inc. (NYSE: HYT), BlackRock Credit Allocation Income Trust (NYSE: BTZ), BlackRock Limited Duration Income Trust (NYSE: BLW), BlackRock Core Bond Trust (NYSE: BHK), and BlackRock Multi-Sector Income Trust (NY